Taysha Gene Therapies (TSHA) Total Non-Current Liabilities (2020 - 2026)

Taysha Gene Therapies has reported Total Non-Current Liabilities for 7 years, with the latest figure at $86.8 million in Q1 2026.

• Quarterly Total Non-Current Liabilities rose 5.75% year-over-year to $86.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $86.8 million (up 5.75% YoY) and the FY2025 annual result came in at $94.8 million, up 8.34% from the prior year.
• Total Non-Current Liabilities fell to $86.8 million in Q1 2026 per TSHA's latest filing, from $94.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $241.1 million in Q3 2023 and troughed at $82.1 million in Q1 2025.
• A 5-year average of $106.4 million and a median of $96.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 489.49% in 2022, then slumped 62.64% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $121.2 million in 2022, then dropped by 20.61% to $96.2 million in 2023, then dropped by 9.03% to $87.5 million in 2024, then rose by 8.34% to $94.8 million in 2025, then retreated by 8.44% to $86.8 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $86.8 million, $94.8 million, and $96.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.